Affordable Access

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy.

Authors
  • Gonzalez, G
  • Crombet, T
  • Torres, F
  • Catala, M
  • Alfonso, L
  • Osorio, M
  • Neninger, E
  • Garcia, B
  • Mulet, A
  • Perez, R
  • Lage, R
Type
Published Article
Journal
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Publication Date
Mar 01, 2003
Volume
14
Issue
3
Pages
461–466
Identifiers
PMID: 12598354
Source
Medline
License
Unknown

Abstract

Vaccination with five doses of EGF vaccine is safe and immunogenic. Montanide ISA 51 increased the percentage of GAR. There is a direct relationship between anti-EGF antibody titers and immune response duration with survival time.

Report this publication

Statistics

Seen <100 times